Toll-like receptor 9 agonists as cancer therapeutics

被引：53
|
作者：
Holtick, Udo [1 ,2 ]
Scheulen, Max E. [3 ]
von Bergwelt-Baildon, Michael S. [1 ,2 ]
Weihrauch, Martin R. [1 ,2 ]
机构：
[1] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
[2] Univ Cologne, Lab Transplantat & Tumor Immunol, Max Eder Grp, D-50924 Cologne, Germany
[3] Univ Essen Gesamthsch, W German Canc Ctr, Dept Med Canc Res, Essen, Germany
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2011年 / 20卷 / 03期
关键词：
cancer; immunotherapy; TLR9; agonists; vaccine; BACTERIAL CPG-DNA; PHASE-II TRIAL; NF-KAPPA-B; T-CELLS; IMMUNOSTIMULATORY ACTIVITY; DENDRITIC CELLS; MOLECULAR-PATTERNS; ANTITUMOR-ACTIVITY; INNATE IMMUNITY; GROWTH-FACTOR;
D O I：
10.1517/13543784.2011.553187
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Areas covered: This review summarizes TLR9 signaling and the impact of TLR9 agonists on the immune response. The most recent experimental and clinical data are analyzed as well as the development of new TLR9 agonists in current clinical trials. Expert opinion: Application of TLR9 agonists, in particular, combination strategies with chemo- or radiotherapy seem a promising and efficient immunotherapeutic approach in cancer patients even with refractory disease. Simultaneous application of TLR9 agonists aims at supporting the patient's immune response and overcoming specific immunosuppressant strategies developed by tumors. Combinatory approaches of the future might also seek for synergism of TLR9 agonists with other immunomodulatory strategies such as B-cell activation using the CD40--CD40L system.
引用
收藏
页码：361 / 372
页数：12
相关论文
共 50 条
  • [41] Toll-like receptor 7 and Toll-like receptor 9 agonists effectively enhance immunological memory in Plasmodium chabaudi infected BALB/c mice
    Gao, Wenyan
    Sun, Xiaodan
    Li, Danni
    Sun, Lin
    He, Yang
    Wei, Huanping
    Jin, Feng
    Cao, Yaming
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 81
  • [42] Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
    Christian Rolfo
    Elisa Giovannetti
    Pablo Martinez
    Shannon McCue
    Aung Naing
    npj Precision Oncology, 7
  • [43] Toll-Like Receptor Agonists as Adjuvants for HIV Vaccines
    Stevceva, L.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (33) : 5079 - 5082
  • [44] Toll-Like Receptor Agonists for Treatment of Viral Infections
    Abdel-Magid, Ahmed F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (02): : 153 - 154
  • [45] Plant lectins are novel Toll-like receptor agonists
    Unitt, John
    Hornigold, David
    BIOCHEMICAL PHARMACOLOGY, 2011, 81 (11) : 1324 - 1328
  • [46] Toll-Like Receptor Agonists: Not Just for Vaccines Anymore
    Tomai, Mark
    BIOPHARM INTERNATIONAL, 2011, 24 (01) : S15 - S16
  • [47] MICROGLIAL RESPONSES TO ENDOGENOUS TOLL-LIKE RECEPTOR AGONISTS
    Hanisch, U. K.
    Moeller, T.
    GLIA, 2009, 57 (13) : S6 - S6
  • [48] Systemic cancer immunotherapy with Toll-like receptor 7 agonists Timing is everything
    Hotz, Christian
    Bourquin, Carole
    ONCOIMMUNOLOGY, 2012, 1 (02) : 227 - 228
  • [49] Safety of Toll-like receptor 9 agonists: a systematic review and meta-analysis
    Qin, Mei
    Li, Yong
    Yang, Xu
    Wu, HongQuan
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2014, 36 (04) : 251 - 260
  • [50] Impact of Secondary Structure of Toll-Like Receptor 9 Agonists on Interferon Alpha Induction
    Yu, Dong
    Putta, Mallikarjuna R.
    Bhagat, Lakshmi
    Dai, Meiru
    Wang, Daqing
    Trombino, Anthony F.
    Sullivan, Tim
    Kandimalla, Ekambar R.
    Agrawal, Sudhir
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (12) : 4320 - 4325
12345